Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
Date:2/24/2011

NANJING, China, Feb. 24, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2010 on Tuesday, March 8, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, March 8 at 9 p.m. Beijing/Hong Kong time).To access the conference call, please dial:United States toll-free:

+1.866.831.5605International:

+1.617.213.8851China Telecom:

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490China Netcom:

10.800.852.1490 / 10.800.712.2655China 400 (for mobile users)

400.881.1630 / 400.881.1629Hong Kong:

+852.3002.1672Please ask to be connected to Q4 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 56440566

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.888.286.8010 International:

+1.617.801.6888The passcode for replay participants is: 22405893.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.comIn Nanjing:

Yehong Zhang
President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8811In the United States:

Kate Tellier
Brunswick Group
Tel: 1-212-333-3810In Beijing:
Ruirui Jiang
Brunswick Group
Tel: 86-10-5960-8600In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
2. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
3. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
4. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
5. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
6. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
8. Simceres Diosmectite API Passes EU-GMP Inspection
9. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
11. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... 2025" report to their offering. ... The Global Cryostat Market is poised to ... to reach approximately $3.5 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
(Date:3/23/2017)... -- Executive Summary ... research (inputs from industry experts, companies, stakeholders) and ... analysis of global heart valve devices market on ... Procedure By Technique (Mechanical, Bioprosthetic, Transcatheter Aortic Valve ... Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR)), By Region ...
(Date:3/23/2017)... Iowa , March 23, 2017   BioSpace ... career resource, has partnered with Indiana Biosciences Research ... organizations and educational institutions to bring the ... the first-ever BioIndiana Hotbed map, an artistic representation of ... print was presented to Vice President Mike Pence ...
Breaking Medicine Technology:
(Date:3/23/2017)... Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” ... or whose acts have had a significant impact on the careers of all others involved. ... with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction took ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... serving the families and businesses of the Norwalk and Vermillion areas, celebrates ... Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer ...
(Date:3/23/2017)... ... 2017 , ... Benefits delivery trailblazer, Hodges-Mace, LLC, ... benefits dashboard solving one of the top frustrations in employee benefits – how ... time, employees can access up-to-date information and account balances for all of their ...
(Date:3/23/2017)... Angeles, CA (PRWEB) , ... March 23, 2017 ... ... A funding investment in Los Angeles based healthcare technology company California Healthcom Group ... portfolio into the US, and healthcare arena. With headquarters in California, CHG is ...
(Date:3/23/2017)... ... 23, 2017 , ... The TouchPoint Solution, home of Buzzies *, is ... anxiety. , “Buzzies change the way we interact with stress and live our ... its launch date in December 2016, The TouchPoint Solution has sold more than $750,000 ...
Breaking Medicine News(10 mins):